Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to ma...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Apostolos Tsiachristas, Grant Vallance, Rositsa Koleva-Kolarova, Harriet Taylor, Luke Solomons, Giovanni Rizzo, Catherine Chaytor, Junel Miah, Sarah Wordsworth, A. Bassim Hassan
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMC 2022-04-01
Serie:BMC Cancer
Länkar:https://doi.org/10.1186/s12885-022-09576-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk